Neurimmune to regain global rights to brain amyloid depleter for the treatment of Alzheimer’s disease
January 31, 2024 07:45 ET
|
Neurimmune AG
ZURICH, Switzerland, Jan. 31, 2024 (GLOBE NEWSWIRE) -- Neurimmune announced today that it regained global rights to aducanumab, a recombinant human antibody developed to deplete brain amyloid....